RhumbLine Advisers’s Adaptimmune Therapeutics ADAP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | – | Sell |
-3,661
| Closed | -$72 | – | 4130 |
|
|
2026
Q1 | $72 | Hold |
3,661
| – | – | ﹤0.01% | 4058 |
|
|
2025
Q4 | $95 | Sell |
3,661
-2,082
| -36% | -$283 | ﹤0.01% | 4088 |
|
|
2025
Q3 | $745 | Sell |
5,743
-2,790
| -33% | -$383 | ﹤0.01% | 4038 |
|
|
2025
Q2 | $2.05K | Sell |
8,533
-9,780
| -53% | -$2.61K | ﹤0.01% | 3998 |
|
|
2025
Q1 | $3.6K | Sell |
18,313
-1,435
| -7% | -$743 | ﹤0.01% | 3941 |
|
|
2024
Q4 | $10.6K | Buy |
19,748
+588
| +3% | +$428 | ﹤0.01% | 3874 |
|
|
2024
Q3 | $18.2K | Buy |
19,160
+2,439
| +15% | +$2.77K | ﹤0.01% | 3825 |
|
|
2024
Q2 | $16.3K | Buy |
16,721
+9,599
| +135% | +$10.5K | ﹤0.01% | 3900 |
|
|
2024
Q1 | $11.3K | Buy |
7,122
+1,210
| +20% | +$1.46K | ﹤0.01% | 3847 |
|
|
2023
Q4 | $4.69K | Buy |
5,912
+330
| +6% | +$186 | ﹤0.01% | 3991 |
|
|
2023
Q3 | $4.35K | Hold |
5,582
| – | – | ﹤0.01% | 4007 |
|
|
2023
Q2 | $5.16K | Buy |
+5,582
| New | +$6.66K | ﹤0.01% | 4072 |
|
RhumbLine Advisers's ADAP Position: Q2 2026 in Review
RhumbLine Advisers sold out of Adaptimmune Therapeutics (ADAP) in Q2 2026, closing a stake of 3,661 shares — an estimated $72 sold.
RhumbLine Advisers first reported a position in ADAP in Q2 2023 and held it in 12 quarters. The position peaked at $18.2K in Q3 2024. 0 funds tracked by Wall St. Rank hold ADAP as of Q2 2026.
- RhumbLine Advisers reported no remaining Adaptimmune Therapeutics position as of Q2 2026 after selling out during the quarter.
- RhumbLine Advisers sold 3,661 Adaptimmune Therapeutics shares in Q2 2026, an estimated $72.
- RhumbLine Advisers first reported a position in Adaptimmune Therapeutics in Q2 2023 and held it in 12 quarters.
- RhumbLine Advisers's Adaptimmune Therapeutics position peaked at $18.2K in Q3 2024.
- 0 funds tracked by Wall St. Rank held Adaptimmune Therapeutics as of Q2 2026.
Based on RhumbLine Advisers's 13F filing for Q2 2026, filed 12 Aug 2026.